Nitric oxide, oxygen, and prostacyclin in children with pulmonary hypertension

被引:21
作者
Turanlahti, MI
Laitinen, PO
Sarna, SJ
Pesonen, E
机构
[1] Univ Helsinki, Hosp Children & Adolescents, Dept Paediat Cardiol, Div Paediat, FIN-00290 Helsinki, Finland
[2] Univ Helsinki, Dept Publ Hlth, Helsinki, Finland
[3] Univ Lund Hosp, Dept Paediat, S-22185 Lund, Sweden
关键词
pulmonary hypertension; nitric oxide; prostacyclin; congenital heart disease; children;
D O I
10.1136/hrt.79.2.169
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective - To test the vasodilatory response of the pulmonary vascular bed in children with pulmonary hypertension. Design - Prospective dose response study in which the effects of inhaled nitric oxide (NO) are compared with those of oxygen and intravenous prostacyclin. Patients and interventions - The vasodilator test was performed in 20 patients in whom mean pulmonary artery pressure (PAPm) was greater than or equal to 40 mm Hg and/or pulmonary vascular resistance index was greater than or equal to 4 Um(2). Haemodynamic effects of inhaled NO (20, 40, and 80 ppm) at a fractional inspired oxygen (FiO2) value of 0.3, pure oxygen, oxygen at FiO2 0.9-1.0 combined with NO as above or with intravenous prostacyclin at 10 and 20 ng/kg/min were measured. Result - NO decreased PAPm with a dose response from 20 to 40 ppm (mean change at 40 ppm -5.50, 95% confidence interval (CI) -7.98 to -3.02 mm Hg). Maximal decrease in the ratio of pulmonary to systemic vascular resistance was achieved with a combination of NO 80 ppm and oxygen (-0.18, 95% CI -0.26 to -0.10). Increase in the pulmonary flow index was greatest with pure oxygen in those with an intracardiac shunt (8.52, 95% CI -0.15 to 17.20 1/min/m(2)). Neither NO nor oxygen altered systemic arterial pressure but intravenous prostacyclin lowered systemic arterial pressure and resistance. Conclusions - NO selectively reduces pulmonary vascular resistance and pressure maximally at 40 ppm. Oxygen reduces pulmonary vascular resistance and NO potentiates this reduction without affecting the systemic circulation. Prostacyclin vasodilates the pulmonary and the systemic circulations.
引用
收藏
页码:169 / 174
页数:6
相关论文
共 29 条
[1]   INHALED NITRIC-OXIDE AND HEMODYNAMIC EVALUATION OF PATIENTS WITH PULMONARY-HYPERTENSION BEFORE TRANSPLANTATION [J].
ADATIA, I ;
PERRY, S ;
LANDZBERG, M ;
MOORE, P ;
THOMPSON, JE ;
WESSEL, DL .
JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1995, 25 (07) :1656-1664
[2]  
Adatia Ian, 1994, Current Opinion in Pediatrics, V6, P583, DOI 10.1097/00008480-199410000-00014
[3]  
BEGHETTI M, 1995, BRIT HEART J, V73, P65
[4]   RELIEF OF SEVERE PULMONARY-HYPERTENSION AFTER CLOSURE OF A LARGE VENTRICULAR SEPTAL-DEFECT USING LOW-DOSE INHALED NITRIC-OXIDE [J].
BERNER, M ;
BEGHETTI, M ;
RICOU, B ;
ROUGE, JC ;
PRETRE, R ;
FRIEDLI, B .
INTENSIVE CARE MEDICINE, 1993, 19 (02) :75-77
[5]   Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease [J].
Berner, M ;
Beghetti, M ;
SpahrSchopfer, I ;
Oberhansli, I ;
Friedli, B .
AMERICAN JOURNAL OF CARDIOLOGY, 1996, 77 (07) :532-+
[6]   PROLONGED INHALATION OF LOW CONCENTRATIONS OF NITRIC-OXIDE IN PATIENTS WITH SEVERE ADULT-RESPIRATORY-DISTRESS-SYNDROME - EFFECTS ON PULMONARY HEMODYNAMICS AND OXYGENATION [J].
BIGATELLO, LM ;
HURFORD, WE ;
KACMAREK, RM ;
ROBERTS, JD ;
ZAPOL, WM .
ANESTHESIOLOGY, 1994, 80 (04) :761-770
[7]   DOES PROSTACYCLIN ENHANCE THE SELECTIVE PULMONARY VASODILATOR EFFECT OF OXYGEN IN CHILDREN WITH CONGENITAL HEART-DISEASE [J].
BUSH, A ;
BUSST, C ;
BOOTH, K ;
KNIGHT, WB ;
SHINEBOURNE, EA .
CIRCULATION, 1986, 74 (01) :135-144
[8]   IMPAIRMENT OF ENDOTHELIUM-DEPENDENT PULMONARY-ARTERY RELAXATION IN CHILDREN WITH CONGENITAL HEART-DISEASE AND ABNORMAL PULMONARY HEMODYNAMICS [J].
CELERMAJER, DS ;
CULLEN, S ;
DEANFIELD, JE .
CIRCULATION, 1993, 87 (02) :440-446
[9]   EFFECTS OF EXPOSURE OF BLOOD HEMOGLOBIN TO NITRIC-OXIDE [J].
CHIODI, H ;
MOHLER, JG .
ENVIRONMENTAL RESEARCH, 1985, 37 (02) :355-363
[10]  
DINHXUAN AT, 1989, BRIT J PHARMACOL, V99, P9